Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 8

1.

The business case for quality: economic analysis of the Michigan Keystone Patient Safety Program in ICUs.

Waters HR, Korn R Jr, Colantuoni E, Berenholtz SM, Goeschel CA, Needham DM, Pham JC, Lipitz-Snyderman A, Watson SR, Posa P, Pronovost PJ.

Am J Med Qual. 2011 Sep-Oct;26(5):333-9. doi: 10.1177/1062860611410685.

PMID:
21856956
[PubMed - indexed for MEDLINE]
2.

Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy.

Burchardi H, Schneider H.

Pharmacoeconomics. 2004;22(12):793-813. Review.

PMID:
15294012
[PubMed - indexed for MEDLINE]
3.

Economic aspects of preventing health care-associated infections in the intensive care unit.

Zilberberg MD, Shorr AF.

Crit Care Clin. 2012 Jan;28(1):89-97, vi-vii. doi: 10.1016/j.ccc.2011.10.005. Review.

PMID:
22123101
[PubMed - indexed for MEDLINE]
4.

The impact of ventilator-associated pneumonia on the Canadian health care system.

Muscedere JG, Martin CM, Heyland DK.

J Crit Care. 2008 Mar;23(1):5-10. doi: 10.1016/j.jcrc.2007.11.012. Review.

PMID:
18359415
[PubMed - indexed for MEDLINE]
5.

Infection prevention in the intensive care unit.

Barsanti MC, Woeltje KF.

Infect Dis Clin North Am. 2009 Sep;23(3):703-25. doi: 10.1016/j.idc.2009.04.012. Review.

PMID:
19665091
[PubMed - indexed for MEDLINE]
6.

Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs.

Umscheid CA, Mitchell MD, Doshi JA, Agarwal R, Williams K, Brennan PJ.

Infect Control Hosp Epidemiol. 2011 Feb;32(2):101-14. doi: 10.1086/657912. Review.

PMID:
21460463
[PubMed - indexed for MEDLINE]
7.

[Non-pharmacological prevention of ventilator-associated pneumonia].

Díaz LA, Llauradó M, Rello J, Restrepo MI.

Arch Bronconeumol. 2010 Apr;46(4):188-95. doi: 10.1016/j.arbres.2009.08.001. Epub 2009 Oct 9. Review. Spanish.

PMID:
19819060
[PubMed - indexed for MEDLINE]
Free Article
8.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk